Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. NVDA
9. BLZE
10. NKE

Go back to Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results

Esperion Therapeutics (ESPR) Misses Q2 EPS by 15c

August 8, 2019 7:38 AM EDT

Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($2.01), $0.15 worse than the analyst estimate of ($1.86). Revenue for the quarter came in at $982 thousand versus the consensus estimate of $930 thousand.

This year continues the momentum weve come to expect from our team of Lipid Management... More